TrialBridgeNCT06574880
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Recruiting · Phase 1, Phase 2 · Angela Y. Jia, MD PhD · registry updated 2026-05-26
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.
Inclusion
- Participant must be ≥ 18 years of age.
- ECOG performance status ≤ 1
- Histologic confirmation of prostate adenocarcinoma of the prostate
- PSMA avid disease on PSMA PET/CT, where the tumor in the prostate has SUVmax ≥ 10.
- PSMA PET/CT must be obtained within 4 months.
- Need ≥ 1 criteria:
Exclusion
- Clinical or radiographic evidence of distant metastatic disease (M1a above aortic bifurcation, M1b, or M1c) by any imaging. Participants are allowed to M1a nodal disease that is below the aortic bifurcation. Negative PSMA PET/CT is an acceptable substitute to conventional staging.
- Prostate gland size \>90 cc measured by CT, ultrasound, or MRI
- Prior head and neck radiation therapy.
- Prior treatment for prostate cancer (incudes chemotherapy, radiation therapy, or anti-androgen therapy).
- Prohibited within 30 days prior to administration to study treatment: spironolactone and other investigational drug therapies.
- Prohibited 3 months before participant registration and during administration of study treatment: oral ketoconazole, , estrogens, and radiopharmaceuticals.